Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda diabetes drug reduces risk of repeat heart attacks
The findings build on previous study results showing that Actos, an oral anti-diabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16% in
The findings build on previous study results showing that Actos, an oral anti-diabetic medication, significantly reduced the combined risk of heart attacks, strokes and death by 16% in
The researchers investigated the benefits of using a patient’s own (autologous) selected adult stem cells, called CD34+ cells, to treat coronary artery disease. A total of 24 patients
State Food and Drug Administration (SFDA) has approved H101, an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory
The vaccine candidate uses the Adenovirus-35 vector technology and expresses HIV-1 antigens. Building on Transgene’s viral vectors manufacturing processes and long experience in the field, two vaccine batches
In the collaboration, the DNA methylation status of the MGMT gene is being evaluated for its potential role in optimizing Temodar therapy in patients with glioblastoma multiforme brain
The study did not meet its primary endpoint of a statistically significant reduction in 180-day all-cause mortality although it did produce a slight improvement in mortality rate over
The study, published in the November issue of Cancer Epidemiology Biomarkers & Prevention, was conducted by a team from Johns Hopkins University School of Medicine and Bloomberg School
The studies will evaluate the ability of CTCE-9908 to inhibit the signaling and function of the CXCR4 receptor found on prostate cancer cells. The CXCR4 receptor, present on
The last decade has marked a major improvement in the treatment of HIV positive patients thanks to the highly active anti-retroviral treatment (HAART) consisting of a cocktail of
In this dose-ranging trial, more than 60% of patients with moderately to severely active rheumatoid arthritis (RA) treated with golimumab and methotrexate experienced at least 20% improvement in